For the significant portion of people who won't self-inject either because of needle phobia or practical reasons that's a genuine differentiator, not a marketing footnote
Mutations in various proteins such as leucine-rich repeat kinase 2 (LRRK2
The potential of GLP-1/glucagon dual receptor agonist on steatohepatitis, fibrosis and liver regeneration has also shown some promising results in clinical studies (55) and may have a therapeutic potential in NAFLD
While some fatigue is common during early weight loss, progressive weakness, particularly if accompanied by muscle pain or cramping, may suggest inadequate protein intake, electrolyte imbalances, or other metabolic concerns that require evaluation
As of now, there are zero randomized clinical trials studying BPC-157 in humans, and the safety and efficacy profile remains unconfirmed